Prediction and identification of B‑cell epitopes for tumor necrosis factor‑α

Zhang,Jun; Cui,Ying; Wu,Yinfang; Wang,Huiju; Ke,Jinjing

doi:10.3892/mmr.2017.7007

Prediction and identification of B‑cell epitopes for tumor necrosis factor‑α

Authors:
- Jun Zhang
- Ying Cui
- Yinfang Wu
- Huiju Wang
- Jinjing Ke
View Affiliations

Affiliations: Department of Gastroenterology, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, Department of Nuclear Medicine, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China, The Second Clinical Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang 310053, P.R. China, Key Laboratory of Gastroenterology of Zhejiang, Zhejiang Provincial People's Hospital, Hangzhou, Zhejiang 310014, P.R. China
Published online on: July 15, 2017 https://doi.org/10.3892/mmr.2017.7007
Pages: 3439-3444

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to predict and identify B‑cell epitopes for mouse tumor necrosis factor‑α (mTNF‑α). DNAStar and BcePred software were used to predict B‑cell epitopes for mTNF‑α. A predicted eight‑branch multiple antigenic polypeptide (MAP) was synthesized and used to immunize BALB/c mice, combined with a promiscuous helper interleukin‑1β epitope (VQGEESNDK, amino acids 163‑171). The serum titer was measured. The specificity and avidity were determined by western blotting and indirect enzyme‑linked immunosorbent assay (ELISA). Amino acids 54‑65 (MAP1) and 78‑92 (MAP2) of mTNF‑α were predicted as most likely to be B‑cell epitopes. Dynamic monitoring of antibody concentration demonstrated that MAP1 and MAP2 may induce the production of specific antibodies with a higher antibody level for MAP2. Furthermore, MAP1 and MAP2 were confirmed to induce mTNF‑α‑specific antibodies by western blotting. Indirect ELISA was used to confirm that MAP2 had the highest affinity with commercial anti‑mTNF‑α antibody. Amino acids 54‑65 and 78‑94 of mTNF‑α are B‑cell epitopes, wherein amino acids 78‑94 have the strongest immunogenicity. The present study provides a theoretical basis for further research into the mTNF‑α polypeptide antibody and a B‑cell MAP vaccine.

View Figures

View References

1	Park JH and Brentjens RJ: Adoptive immunotherapy for B-cell malignancies with autologous chimeric antigen receptor modified tumor targeted T cells. Discov Med. 9:277–288. 2010.PubMed/NCBI
2	Castro FV, Al-Muftah M, Mulryan K, Jiang HR, Drijfhout JW, Ali S, Rutkowski AJ, Kalaitsidou M, Gilham DE and Stern PL: Regulation of autologous immunity to the mouse 5T4 oncofoetal antigen: Implications for immunotherapy. Cancer Immunol Immunother. 61:1005–1018. 2012. View Article : Google Scholar : PubMed/NCBI
3	Kopylov U, Ben-Horin S, Zmora O, Eliakim R and Katz LH: Anti-tumor necrosis factor and postoperative complications in Crohn's disease: Systematic review and meta-analysis. Inflamm Bowel Dis. 18:2404–2413. 2012. View Article : Google Scholar : PubMed/NCBI
4	Kawalec P, Mikrut A, Wiśniewska N and Pilc A: Tumor necrosis factor-α antibodies (infliximab, adalimumab and certolizumab) in Crohn's disease: Systematic review and meta-analysis. Arch Med Sci. 9:765–779. 2013. View Article : Google Scholar : PubMed/NCBI
5	Marchioni RM and Lichtenstein GR: Tumor necrosis factor-α inhibitor therapy and fetal risk: A systematic literature review. World J Gastroenterol. 19:2591–2602. 2013. View Article : Google Scholar : PubMed/NCBI
6	Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, et al: Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: A parallel, open-label randomised controlled trial. Lancet. 380:1909–1915. 2012. View Article : Google Scholar : PubMed/NCBI
7	Reinisch W, Sandborn WJ, Rutgeerts P, Feagan BG, Rachmilewitz D, Hanauer SB, Lichtenstein GR, de Villiers WJ, Blank M, Lang Y, et al: Long-term infliximab maintenance therapy for ulcerative colitis: The ACT-1 and −2 extension studies. Inflamm Bowel Dis. 18:201–211. 2012. View Article : Google Scholar : PubMed/NCBI
8	Jun Y, Hong Z and Jie T: The study of mouse TNF-α functional domain and its neutralizing antibody binding site. Prog Biochem Biophys. 36:4302009.
9	Amexis G and Young NS: Multiple antigenic peptides as vaccine platform for the induction of humoral responses against dengue-2 virus. Viral Immunol. 20:657–663. 2007. View Article : Google Scholar : PubMed/NCBI
10	Dechamma HJ, Dighe V, Kumar CA, Singh RP, Jagadish M and Kumar S: Identification of T-helper and linear B epitope in the hypervariable region of nucleocapsid protein of PPRV and its use in the development of specific antibodies to detect viral antigen. Vet Microbiol. 118:201–211. 2006. View Article : Google Scholar : PubMed/NCBI
11	Thorlund K, Druyts E, Mills EJ, Fedorak RN and Marshall JK: Adalimumab versus infliximab for the treatment of moderate to severe ulcerative colitis in adult patients naïve to anti-TNF therapy: An indirect treatment comparison meta-analysis. J Crohns Colitis. 8:571–581. 2014. View Article : Google Scholar : PubMed/NCBI
12	Fausel R and Afzali A: Biologics in the management of ulcerative colitis-comparative safety and efficacy of TNF-α antagonists. Ther Clin Risk Manag. 11:63–73. 2015.PubMed/NCBI
13	Marehbian J, Arrighi HM, Hass S, Tian H and Sandborn WJ: Adverse events associated with common therapy regimens for moderate-to-severe Crohn's disease. Am J Gastroenterol. 104:2524–2533. 2009. View Article : Google Scholar : PubMed/NCBI
14	Can super-antibody drugs be tamed? Nature. 440:855–856. 2006.PubMed/NCBI
15	Rolinski J and Hus I: Breaking immunotolerance of tumors: A new perspective for dendritic cell therapy. J Immunotoxicol. 11:311–318. 2014. View Article : Google Scholar : PubMed/NCBI
16	Park KB, Lim BK, Ye MB, Chung SY and Nam JH: A peptide vaccine based on a B-cell epitope on the VP1 protein of enterovirus 70 induces a strong antibody response. Acta Virol. 56:337–342. 2012. View Article : Google Scholar : PubMed/NCBI
17	Haro I and Gómara MJ: Design of synthetic peptidic constructs for the vaccine development against viral infections. Curr Protein Pept Sci. 5:425–433. 2004. View Article : Google Scholar : PubMed/NCBI
18	Zhang J, Yang JM, Wang HJ, Ru GQ and Fan DM: Synthesized multiple antigenic polypeptide vaccine based on B-cell epitopes of human heparanase could elicit a potent antimetastatic effect on human hepatocellular carcinoma in vivo. PLoS One. 8:e529402013. View Article : Google Scholar : PubMed/NCBI
19	Zhang J, Yang J, Fan D, Tao H, Wang H and Yu T: Peptide FLNPDVLDI of heparanase is a novel HLA-A2-restricted CTL epitope and elicits potent immunological antitumor effects in vitro with an 8-branched design. Oncol Rep. 29:1955–1961. 2013.PubMed/NCBI
20	Zhang J, Fan DM and Yang JM: Immunotherapy targeting Heparanase-1 may be the the dawn of cancer sufferers. J Gastroen Hepatol Res. 1:32012.
21	Zhang J, Yang J, Han X, Zhao Z, Du L, Yu T and Wang H: Overexpression of heparanase multiple antigenic peptide 2 is associated with poor prognosis in gastric cancer: Potential for therapy. Oncol Lett. 4:178–182. 2012.PubMed/NCBI
22	Zhang J, Yang J, Cai Y, Jin N, Wang H and Yu T: Multiple antigenic polypeptide composed of heparanase B-cell epitopes shrinks human hepatocellular carcinoma in mice. Oncol Rep. 33:1248–1256. 2015.PubMed/NCBI
23	Du L, Wang H, Yang J, Gao H, Zhou Y and Tao H: T-helper epitope peptide improves immunological effects of the B cell epitopes of human heparanase protein. Chin J Microbiol Immunol. 869–872. 2008.